Amyloid Beta Oligomer Binding Molecule for Selective Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic methods for Alzheimer's disease lack effective tools to selectively measure amyloid beta oligomers, which are crucial for disease diagnosis and progression monitoring, due to the high levels of monomers and fibrils in cerebrospinal fluid, and existing monoclonal antibodies have limitations such as restricted activity and instability.
Innovation Solution
Development of an amyloid beta peptide-specific antigen binding molecule with an affinity for oligomers of less than 1 nM and at least 50-fold greater specificity for oligomers than for fibrils, comprising specific amino acid sequences and structures, and its use in diagnostic and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to detect amyloid beta oligomers, then therapeutic treatment can be provided, but the antibodies have limited specificity and bind to both monomers and fibrils reducing diagnostic accuracy
Solution Approach 1:
The invention divides the antibody structure into separate functional domains: a variable domain (VH or VNAR) for specific oligomer binding and a constant domain for effector functions. This segmentation allows independent optimization of binding specificity and therapeutic activity.
Solution Approach 2:
The invention creates antibodies with non-uniform binding properties across different amyloid beta forms by engineering specific CDR regions. The CDR3 loop is specifically designed to recognize conformational epitopes on oligomers while avoiding binding to monomers and fibrils, creating localized binding specificity.
2Measurement precision
If assays are designed to measure amyloid beta oligomers in cerebrospinal fluid, then disease diagnosis and monitoring can be achieved, but the high levels of monomers (1,000 to 10,000 fold higher) overwhelm the detection capability
Solution Approach 1:
The invention changes the binding parameters of the antibody by engineering specific CDR sequences (particularly CDR3) that confer conformational specificity. This allows the antibody to recognize the unique three-dimensional structure of oligomers while ignoring the linear sequence similarity shared with monomers and fibrils.
Solution Approach 2:
The invention replaces conventional whole antibody binding mechanisms with a domain-based binding approach using VH or VNAR fragments. This substitution enables finer control over binding specificity through engineered CDR regions while reducing steric hindrance and non-specific interactions.
3Reliability
If conventional monoclonal antibodies are used for therapy, then treatment can be provided, but product instability and aggregation occur reducing reliability
Solution Approach 1:
The invention extracts only the essential antigen-binding domain (VH or VNAR) from the complete antibody structure, removing regions prone to aggregation and instability. This minimalistic approach retains binding functionality while improving stability and reducing immunogenicity.
Solution Approach 2:
The invention uses smaller, more stable antibody fragments (VH or VNAR domains of ~12-15 kDa) instead of full-length antibodies. These smaller units are more stable, easier to manufacture, and can be administered as single-use formulations with reduced aggregation risk.
4Measurement precision
If selective oligomer detection is achieved, then accurate diagnosis can be provided, but existing methods lack the required selectivity over monomers and fibrils
Solution Approach 1:
Instead of trying to enhance binding to oligomers, the invention inverts the approach by designing antibodies that specifically avoid binding to monomers and fibrils. The CDR regions are engineered to recognize conformational features unique to oligomers, creating negative selection against other forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding molecule enables selective detection and reduction of amyloid beta oligomers, facilitating accurate diagnosis and treatment of Alzheimer's disease and other neurodegenerative conditions, with improved specificity and stability compared to existing methods.
Implementation Method 1
an amyloid beta peptide (Aβ)-oligomer-specific antigen binding molecule displaying the following characteristics: an affinity for Aβ-oligomers of less than 1 nM
Data Source
AI summary
This disclosure relates to an amyloid beta peptide (Aβ)-oligomer-specific antigen binding molecule and the use thereof as a diagnostic agent or as a therapeutic agent for the treatment or prevention of Alzheimer's Disease, Down's syndrome, mild cognitive impairment, cerebral amyloid angiopathy, vascular dementia, multi-infarct dementia, Parkinson's disease, Dementia with Lewy Bodies, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, or Gaucher's disease.